Clearside Biomedical, Inc. (CLSD) Stock
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc. is headquartered in US.
Clearside Biomedical, Inc. (CLSD) stock trades at $0.41 with a market capitalization of $2.15M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.11, reflecting a net loss over the last twelve months, a negative price-to-book of -0.04, reflecting negative shareholders' equity, price-to-sales of 0.71. Over the past 52 weeks the stock has ranged between $0.31 and $17.10, and currently trades 97.6% below its 52-week high.
On profitability, Clearside Biomedical, Inc. generates a return on equity (ROE) of 37.73% (not meaningful, as shareholders' equity is negative), return on capital employed of -178.25%, an operating margin of -523.09%, a net profit margin of -618.26%.
Official website: www.clearsidebio.com
Clearside Biomedical, Inc. by the numbers, 2015–2024
Between 2015 and 2024 Clearside Biomedical, Inc. reported revenue of $0 rising to $2.0M. Compounded, revenue has grown 0.0% a year over five years, -59.5% over three, -75.0% over the last twelve months. Net profit fell to $-34.0M.
The most recent net margin is -618.26%. On a trailing twelve-month basis to Sep '25, revenue is $2.0M and net profit $-25.0M.
Borrowings rose from $6.0M to $52.0M, cash on hand is $6.8M, cash from operations was $-25.0M in the latest year, positive in 0 of the last 10.
Return on equity has averaged -42.6% over five years, and was 87.2% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Clearside Biomedical, Inc. (CLSD) — frequently asked questions
What is Clearside Biomedical, Inc. (CLSD) stock price today?
Clearside Biomedical, Inc. (CLSD) is currently trading at $0.41, up 0% today.
What is CLSD P/E ratio?
Clearside Biomedical, Inc.'s P/E ratio is -0.11. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is CLSD return on equity (ROE)?
Clearside Biomedical, Inc.'s return on equity (ROE) is 37.73%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.
What is Clearside Biomedical, Inc.'s market cap?
Clearside Biomedical, Inc. has a market capitalization of $2.15M.
Does CLSD pay a dividend?
Clearside Biomedical, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does CLSD carry?
Clearside Biomedical, Inc. has a debt-to-equity ratio of -0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is CLSD's profit margin?
Clearside Biomedical, Inc. reports a net profit margin of -618.26% — the share of revenue left after every cost, including tax and interest.
What sector is CLSD in?
Clearside Biomedical, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is CLSD listed on?
Clearside Biomedical, Inc. trades on NASDAQ under the ticker CLSD.
What is CLSD's 52-week range?
Over the last year Clearside Biomedical, Inc. has traded between $0.31 and $17.10.
Related Healthcare Stocks
Popular Stocks
Screens CLSD currently matches
On the figures above, Clearside Biomedical, Inc. passes the filters for 3 of our ready-made screens, among them Penny Stocks, Stocks Under $1, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.